Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder

Abstract

OBJECTIVES To evaluate the relationship between prostate stem cell antigen (PSCA) expression level in transitional cell carcinoma (TCC) of the urinary bladder and various clinicopathological features, including stage and grade; and to determine whether PSCA mRNA expression predicts disease recurrence in superficial (not muscle‐invasive) TCC of the bladder. PATIENTS AND METHODS Real‐time reverse transcriptase‐polymerase chain reaction (RT‐PCR) was performed on 97 TCC tissue samples and in 36 samples of normal bladder urothelium; the findings were analysed in relation to clinicopathological factors. Immunohistochemical expression was examined using light and confocal immunofluorescence microscopy to validate the RT‐PCR data. RESULTS Twenty‐seven patients developed disease recurrence, while the remaining 22 had no evidence of recurrence of superficial TCC of the bladder. There was significantly higher PSCA mRNA expression in TCC than in normal urothelium samples (P = 0.008). Superficial (TaT1) tumours had significantly higher PSCA expression than muscle‐invasive (≥ pT2) tumours (P < 0.001). There was no significant difference between patients with G1–2 tumours and those with G3 tumours (P = 0.109). Immunohistochemical analysis showed markedly greater PSCA expression in superficial than invasive TCC. Notably, from a multivariate analysis, the expression level of PSCA was an independent predictor of disease recurrence in superficial TCC (P = 0.012). CONCLUSIONS These findings suggest that the PSCA expression level measured by real‐time RT‐PCR could be a valuable prognostic marker for tumour recurrence in superficial TCC of the bladder.

Prostate stem cell antigen rs2294008 (C>T) polymorphism and bladder cancer risk: a meta-analysis based on cases and controls

“…Previous studies have shown that PSCA was initially identified as a prostate-specific cell-surface antigen (Argani et al, 2001), and that it is highly expressed in prostate cancer and other non-prostatic malignancies, such as gastric cancer, pancreatic cancer, and bladder cancer (Elsamman et al, 2006;Grubbs et al, 2006). Studies have also reported the differential expression of PSCA in these tumors, and significant discrepancies among its genetic polymorphisms (Elsamman et al, 2006;Feng et al, 2008). Among these variants, rs2294008 (C>T) is the most widely studied.…”

Genetic variant in PSCA predicts survival of diffuse‐type gastric cancer in a Chinese population

“…8 Several other non-prostatic malignancies including bladder cancer, clear renal cell cancer, pancreatic cancer and gastric cancer were identified to express PSCA as well. [9][10][11][12] It has been found that PSCA is expressed in differentiating gastric epithelial cells, has a cell-proliferation inhibition activity in vitro and is frequently silenced in gastric cancer. 12 In normal stomach, PSCA is expressed at the isthmus of the gastric gland, which may harbor proliferating precursor cells, and may inhibit cell proliferation acting as a tumor suppressor.…”

Expression of PSCA, PIWIL1, and TBX2 in Endometrial Adenocarcinoma

“…Subsequently, several othertumorswereevaluatedforPSCAexpressionincluding pancreatic adenocarcinoma [10][11][12], transitional cell carcinoma [9,13],renalcellcarcinoma [14],anddiffuse-typegastriccancer [15].…”